Guardant Health, Inc. $GH Shares Sold by PDT Partners LLC

PDT Partners LLC reduced its stake in Guardant Health, Inc. (NASDAQ:GH) by 13.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 207,713 shares of the company’s stock after selling 32,760 shares during the quarter. Guardant Health makes up 0.6% of PDT Partners LLC’s investment portfolio, making the stock its 8th largest holding. PDT Partners LLC’s holdings in Guardant Health were worth $8,849,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also modified their holdings of GH. SVB Wealth LLC acquired a new stake in shares of Guardant Health in the first quarter worth $54,000. NewEdge Advisors LLC grew its holdings in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock worth $59,000 after purchasing an additional 230 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth about $61,000. GF Fund Management CO. LTD. bought a new stake in shares of Guardant Health in the 4th quarter worth about $79,000. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new stake in Guardant Health during the 1st quarter worth about $97,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Guardant Health news, Director Ian T. Clark sold 6,672 shares of the company’s stock in a transaction on Tuesday, June 17th. The stock was sold at an average price of $48.38, for a total transaction of $322,791.36. Following the completion of the sale, the director directly owned 9,851 shares in the company, valued at $476,591.38. This represents a 40.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Musa Tariq sold 3,213 shares of the business’s stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $49.47, for a total value of $158,947.11. Following the transaction, the director directly owned 7,190 shares of the company’s stock, valued at approximately $355,689.30. The trade was a 30.89% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 235,442 shares of company stock valued at $11,848,325. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Stock Up 4.6%

GH stock opened at $67.42 on Monday. The company has a market cap of $8.41 billion, a PE ratio of -20.13 and a beta of 1.45. The business has a 50-day simple moving average of $51.69 and a 200 day simple moving average of $46.63. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $67.51.

Guardant Health (NASDAQ:GH) last released its earnings results on Wednesday, July 30th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.08. The business had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the previous year, the company earned ($0.84) earnings per share. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Analysts Set New Price Targets

GH has been the topic of a number of research analyst reports. Raymond James Financial increased their price objective on shares of Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, July 31st. Evercore ISI upgraded shares of Guardant Health to a “strong-buy” rating in a report on Monday, July 14th. Scotiabank raised their target price on shares of Guardant Health from $57.00 to $60.00 and gave the stock a “sector outperform” rating in a report on Thursday, July 31st. Mizuho lifted their price objective on shares of Guardant Health from $60.00 to $65.00 and gave the company an “outperform” rating in a report on Friday, June 13th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $60.00 price objective (up from $50.00) on shares of Guardant Health in a report on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating and sixteen have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $57.50.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.